High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2675-2681

  Neben, K ^a   Moehler, T ^a   Egerer, G ^a   Kraemer, A ^a   Hillengass, J ^a   Benner, A ^a   Ho, A D ^a   Goldschmidt, H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BASIC FIBROBLAST GROWTH FACTOR; HEMOGLOBIN; THALIDOMIDE; VASCULOTROPIN;

ADULT; AFFECTIVE NEUROSIS; AGED; ANGIOGENESIS; ARTICLE; BLOOD; BONE MARROW; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MUSCLE WEAKNESS; PARESTHESIA; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SOMNOLENCE; TREMOR; VERTIGO; XEROSTOMIA;

ADULT; AFFECT; AGED; ANGIOGENESIS INHIBITORS; CONSTIPATION; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; EXANTHEMA; FATIGUE; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYPESTHESIA; LYMPHOKINES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SLEEP; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME; TREMOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034802758     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Clinical applications of research on angiogenesis
2. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
3. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
4. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study
5. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
6. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
7. Thalidomide and congeners as anti-inflammatory agents
8. Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes
9. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
10. Differential cytokine modulation and T cell activation by two distinct class of thalidomide analogues that are potent inhibitor of TNF-α
11. Thalidomide is an inhibitor of angiogenesis
12. The treatment of lepra reaction in lepromatous leprosy: Fifteen years of experience with thalidomide
13. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
14. Regression of AIDS-related Kaposi's sarcomas during therapy with thalidomide
15. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
16. Antitumor activity of thalidomide in refractory multiple myeloma
17. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
18. Synergistic effect of vascular endothelial growth factor and basic fibroblast factor on angiogenesis in vivo
19. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth
20. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer
21. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
22. C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system
23. Hypoalbuminemia in patients with multiple myeloma
24. Plateau phase in multiple myeloma: An analysis of long-term follow-up of 432 patients
25. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation
26. Analysis of serial measurements in medical research
27. Censoring distributions as a measure of follow-up in survival analysis
28. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
29. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma
30. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma
31. Infections in myeloma
32. Thalidomide and thrombosis
33. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
34. Thalidomide - A revival story
35. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia